Subsequent Events (Details Narrative)
|
|
|
|
|
|
|
|
|
|
1 Months Ended |
3 Months Ended |
9 Months Ended |
12 Months Ended |
|
|
|
|
|
|
|
|
|
|
|
|
|
Oct. 31, 2024
USD ($)
$ / shares
shares
|
Oct. 21, 2024
USD ($)
$ / shares
shares
|
Oct. 14, 2024
USD ($)
$ / shares
shares
|
Jul. 30, 2024
USD ($)
|
Jun. 13, 2024
USD ($)
shares
|
Mar. 08, 2024
USD ($)
shares
|
Feb. 07, 2024
USD ($)
|
Aug. 31, 2023
d
$ / shares
|
Dec. 28, 2021
USD ($)
$ / shares
shares
|
Oct. 31, 2024
USD ($)
$ / shares
shares
|
Sep. 30, 2024
USD ($)
shares
|
Jun. 30, 2024
USD ($)
shares
|
Mar. 31, 2024
USD ($)
shares
|
Sep. 30, 2023
USD ($)
shares
|
Sep. 30, 2024
USD ($)
shares
|
Sep. 30, 2023
USD ($)
shares
|
Dec. 31, 2023
USD ($)
shares
|
Dec. 31, 2022
USD ($)
$ / shares
shares
|
Dec. 31, 2024
shares
|
Aug. 13, 2024
$ / shares
shares
|
Aug. 06, 2024
USD ($)
|
Jan. 31, 2023
$ / shares
shares
|
Jan. 11, 2023
$ / shares
|
Sep. 30, 2022
USD ($)
|
Aug. 31, 2022
$ / shares
|
Aug. 01, 2022
$ / shares
|
Apr. 30, 2022
$ / shares
|
Apr. 29, 2022
$ / shares
|
Dec. 31, 2021
$ / shares
|
Mar. 09, 2021 |
| Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Convertible notes payable |
|
|
|
|
|
|
|
|
|
|
$ 10,000,000.0
|
|
|
|
$ 10,000,000.0
|
|
$ 10,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Proceeds from issuance of debt |
|
|
|
|
|
|
|
|
$ 494,925
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Outstanding balance percentage |
|
|
|
|
|
|
|
|
10.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.00%
|
|
|
|
|
1.00%
|
| Exercise price | $ / shares |
|
|
|
|
|
|
|
|
$ 8.00
|
|
|
|
|
|
|
|
|
$ 111.04
|
|
|
|
$ 1.93
|
|
|
$ 16.00
|
$ 20.00
|
$ 8.00
|
$ 16.00
|
$ 8.00
|
|
| Expected years |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4 years 6 months
|
|
|
|
|
|
| Proceeds from convertible notes payable |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 3,935,000
|
3,935,000
|
$ 550,715
|
|
|
|
|
|
|
|
|
|
|
|
|
| Repayment of convertible note |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 846,806
|
|
334,444
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common stock issued for cash upon initial public offering and exercise of warrants, net of issuance costs, as restated, shares | shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3,750
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of warrants issued | shares |
|
|
|
|
|
|
|
|
62,500
|
|
|
|
|
|
|
|
|
|
|
|
|
127,260
|
|
|
|
|
|
|
|
|
| Share Price | $ / shares |
|
|
|
|
|
|
|
$ 1.00
|
|
|
|
|
|
|
|
|
|
$ 16.00
|
|
$ 1.00
|
|
|
$ 18.80
|
|
|
|
|
|
|
|
| Consecutive trading days | d |
|
|
|
|
|
|
|
30
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Sale of stock consideration received per transaction |
|
|
|
|
|
|
$ 2,250,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share based payment award description |
|
|
|
|
|
|
(i) one share of the Company’s
common stock, (ii) a warrant to purchase one share of the Company’s common stock exercisable at a purchase price of $18.80 per
share, and (iii) a percentage of equity interest in Diagnostics such that, assuming the sale of all $2,250,000 of Units, SRO LLC will
own a 22% interest in Diagnostics.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Proceeds from issuance of common stock |
|
|
|
|
|
|
$ 4,500,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Restricted stock value |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Convertible debt |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 2,254,856
|
|
|
|
|
|
|
$ 500,000
|
|
|
|
|
|
|
| Purchase Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Escrow deposit |
|
|
|
|
|
|
2,250,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Right offering |
|
|
|
|
|
|
4,500,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Escrow deposit |
|
|
|
|
|
|
$ 2,250,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Initial public offering description |
|
|
|
|
|
|
Unless the parties waive
the conditions to closing, in the event the full $4,500,000 is not raised, whether through SRO LLC or through the Company’s existing
stockholders, the Company will not close on the offering and any funds raised and held in escrow will be returned to investors
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common stock issued for cash upon initial public offering and exercise of warrants, net of issuance costs, as restated, shares | shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
297,625
|
352,443
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share Price | $ / shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 32.00
|
|
|
|
|
|
|
|
|
|
|
|
|
| Restricted stock units | shares |
|
|
|
|
|
|
|
|
|
|
5,002
|
3,722
|
15,625
|
1,876
|
24,349
|
1,876
|
10,650
|
3,500
|
|
|
|
|
|
|
|
|
|
|
|
|
| Restricted stock value |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsequent Event [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Exercise price | $ / shares |
$ 1.42
|
|
|
|
|
|
|
|
|
$ 1.42
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of warrants issued | shares |
329,461
|
|
|
|
|
|
|
|
|
329,461
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Gross proceeds from offering |
|
|
|
$ 10,000,000
|
|
|
|
|
|
$ 3,900,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share Price | $ / shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 1.00
|
|
|
|
|
|
|
|
|
|
|
| Reverse common stock shares outstanding | shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,008,689
|
2,111,235
|
|
|
|
|
|
|
|
|
|
|
| Sale of stock consideration received per transaction |
|
|
|
|
|
|
$ 2,250,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share based payment award description |
|
|
|
|
|
|
(i)
one share of SHPH common stock, (ii) a warrant to purchase one share of SHPH common stock exercisable at a purchase price of $18.80
per share, and (iii) a percentage of equity interest in Diagnostics such that, assuming the sale of all $2,250,000 of Units, SRO LLC
will own a 22% interest in Diagnostics.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Proceeds from issuance of common stock |
|
|
|
|
|
|
$ 4,500,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsequent Event [Member] | Purchase Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Escrow deposit |
|
|
|
|
|
|
2,250,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Right offering |
|
|
|
|
|
|
4,500,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Escrow deposit |
|
|
|
|
|
|
$ 2,250,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Initial public offering description |
|
|
|
|
|
|
Unless the parties waive the conditions to closing, in the event
the full $4,500,000 is not raised, whether through SRO LLC or through SHPH’s existing stockholders, the Company will not close
on the offering and any funds raised and held in escrow will be returned to investors.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsequent Event [Member] | Chief Financial Officer [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Restricted stock units | shares |
|
|
|
|
28,455
|
12,500
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Restricted stock value |
|
|
|
|
$ 100,000
|
$ 41,840
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsequent Event [Member] | Investor [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Convertible debt |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 600,000
|
|
|
|
|
|
|
|
|
|
| Subsequent Event [Member] | Alliance Global Partners [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Exercise price | $ / shares |
$ 1.40
|
|
|
|
|
|
|
|
|
$ 1.40
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Price per share | $ / shares |
$ 1.525
|
|
|
|
|
|
|
|
|
$ 1.525
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Gross proceeds from offering |
$ 4,500,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsequent Event [Member] | Alliance Global Partners [Member] | Common Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Shares issued | shares |
395,574
|
|
|
|
|
|
|
|
|
395,574
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common stock issued for cash upon initial public offering and exercise of warrants, net of issuance costs, as restated, shares | shares |
2,950,820
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of warrants issued | shares |
2,950,820
|
|
|
|
|
|
|
|
|
2,950,820
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsequent Event [Member] | Alliance Global Partners [Member] | Prefunded Warrant [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Exercise price | $ / shares |
$ 0.001
|
|
|
|
|
|
|
|
|
$ 0.001
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common stock issued for cash upon initial public offering and exercise of warrants, net of issuance costs, as restated, shares | shares |
2,555,246
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of warrants issued | shares |
2,555,246
|
|
|
|
|
|
|
|
|
2,555,246
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Price per share | $ / shares |
$ 1.524
|
|
|
|
|
|
|
|
|
$ 1.524
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Sale of stock price per share | $ / shares |
$ 0.001
|
|
|
|
|
|
|
|
|
$ 0.001
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Convertible Bridge Notes [Member] | Subsequent Event [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Convertible notes payable |
|
|
$ 600,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Accruing interest percentage |
|
|
14.50%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Original issue discount percentage |
|
5.00%
|
5.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Proceeds from issuance of debt |
|
$ 220,000
|
$ 570,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Outstanding balance percentage |
|
|
107.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Secured debt |
|
231,579
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Proceeds from secured debt |
|
$ 790,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Convertible Bridge Notes [Member] | Subsequent Event [Member] | Chief Executive Officer [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Proceeds from convertible notes payable |
|
|
$ 237,500
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Repayment of convertible note |
|
|
$ 250,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Convertible Bridge Notes [Member] | Subsequent Event [Member] | Lenders [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants to purchase shares of common stock | shares |
|
88,544
|
240,917
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Exercise price | $ / shares |
|
$ 1.49
|
$ 1.40
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Expected years |
|
5 years
|
5 years
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Convertible Bridge Notes [Member] | Subsequent Event [Member] | Maximum [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Convertible notes payable |
|
|
$ 1,300,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|